HK1249499A1 - 嘧啶類七元環化合物、其製備方法、藥用組合物及其應用 - Google Patents

嘧啶類七元環化合物、其製備方法、藥用組合物及其應用

Info

Publication number
HK1249499A1
HK1249499A1 HK18103236.8A HK18103236A HK1249499A1 HK 1249499 A1 HK1249499 A1 HK 1249499A1 HK 18103236 A HK18103236 A HK 18103236A HK 1249499 A1 HK1249499 A1 HK 1249499A1
Authority
HK
Hong Kong
Prior art keywords
pyrimidine
membered
preparation
pharmaceutical composition
method therefor
Prior art date
Application number
HK18103236.8A
Other languages
English (en)
Inventor
鄧賢明
周大旺
陳蘭芬
何志祥
樊福欽
Original Assignee
安徽省新星藥物開發有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 安徽省新星藥物開發有限責任公司 filed Critical 安徽省新星藥物開發有限責任公司
Publication of HK1249499A1 publication Critical patent/HK1249499A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
HK18103236.8A 2016-03-04 2018-03-07 嘧啶類七元環化合物、其製備方法、藥用組合物及其應用 HK1249499A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610121108 2016-03-04

Publications (1)

Publication Number Publication Date
HK1249499A1 true HK1249499A1 (zh) 2018-11-02

Family

ID=59743511

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103236.8A HK1249499A1 (zh) 2016-03-04 2018-03-07 嘧啶類七元環化合物、其製備方法、藥用組合物及其應用

Country Status (13)

Country Link
US (1) US10975092B2 (zh)
EP (1) EP3424929A4 (zh)
JP (1) JP2019512459A (zh)
KR (1) KR20180114057A (zh)
CN (1) CN107151250B (zh)
AU (1) AU2017226499B2 (zh)
CA (1) CA3012516A1 (zh)
HK (1) HK1249499A1 (zh)
MX (1) MX2018009189A (zh)
RU (1) RU2748696C2 (zh)
TW (1) TWI748996B (zh)
WO (1) WO2017148406A1 (zh)
ZA (1) ZA201805600B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155556B2 (en) 2016-04-07 2021-10-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders
JP7086948B2 (ja) * 2016-10-18 2022-06-20 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド ピリミド－ジアゼピノンキナーゼ骨格化合物およびｄｃｌｋ１／２媒介性障害の治療方法
CN111039944B (zh) * 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
WO2020231726A1 (en) * 2019-05-10 2020-11-19 Dana-Farber Cancer Institute, Inc. Small-molecule focal adhesion kinase (fak) inhibitors
WO2021024141A1 (en) * 2019-08-08 2021-02-11 Xiaoxiang Li Prevention or treatment of diseases and disorders associated with tissue damage
CN113717941B (zh) * 2020-05-26 2023-11-14 中科院合肥技术创新工程院 一种用于喉癌上皮细胞的培养基、培养方法及其应用
KR102498531B1 (ko) * 2020-06-29 2023-02-13 한국과학기술연구원 단백질 카이네이즈 trkc에 선택적인 억제제로서의 신규 피리미도디아제핀 유도체

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101257948A (zh) * 2005-02-18 2008-09-03 阿特努奥恩公司 嘧啶并二氮䓬衍生物及吲哚并蝶啶化合物
US20080242608A1 (en) 2006-06-02 2008-10-02 Azad Bonni Methods and compositions for treating and preventing neurologic disorders
WO2009040556A1 (en) * 2007-09-28 2009-04-02 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US9266890B2 (en) * 2009-01-06 2016-02-23 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP3670515B1 (en) * 2013-03-15 2024-03-06 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2015117087A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives

Also Published As

Publication number Publication date
MX2018009189A (es) 2018-11-09
RU2018124591A (ru) 2020-04-06
NZ744393A (en) 2021-09-24
ZA201805600B (en) 2023-02-22
RU2018124591A3 (zh) 2020-07-24
KR20180114057A (ko) 2018-10-17
EP3424929A4 (en) 2019-08-07
TW201731850A (zh) 2017-09-16
AU2017226499B2 (en) 2020-10-22
WO2017148406A1 (zh) 2017-09-08
TWI748996B (zh) 2021-12-11
RU2748696C2 (ru) 2021-05-28
EP3424929A1 (en) 2019-01-09
CA3012516A1 (en) 2017-09-08
US10975092B2 (en) 2021-04-13
CN107151250B (zh) 2020-03-27
JP2019512459A (ja) 2019-05-16
CN107151250A (zh) 2017-09-12
AU2017226499A1 (en) 2018-09-20
US20200115386A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
IL286165A (en) Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof
LT3453707T (lt) Benzazepino darinys, gamybos būdas, farmacinė kompozicija ir jos naudojimas
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
EP3290420A4 (en) Pyrimidine pyrrole compound, preparation method therefor, pharmaceutical composition, and uses thereof
EP3259272A4 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
EP3130354A4 (en) Posaconazole pharmaceutical composition and preparation method, application and pharmaceutical preparation thereof
ZA201805600B (en) Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof
EP3466943A4 (en) DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL256610B (en) Pyrimidine history, their preparation and pharmaceutical preparations containing them
EP3354653A4 (en) Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
HK1255062A1 (zh) 喹唑啉酮衍生物、其製備方法、藥物組合物及應用
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
EP3181553A4 (en) Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
IL290114A (en) Pharmaceutical preparations, their preparation and uses
HRP20200104T8 (hr) Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto
PL3229843T3 (pl) Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
EP3284743A4 (en) Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
IL262929B1 (en) Preparations for treatment, methods of their preparation and their uses
EP3305283A4 (en) STABILIZED PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARING THE SAME
PL3424911T3 (pl) Pozakonazol, kompozycja, związek pośredni, sposób ich wytwarzania i ich zastosowania
EP3456328A4 (en) COMPOSITION AND USE AND PHARMACEUTICAL PREPARATION THEREOF